Durezol Emulsion
Product Images NDC 66758-086

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Durezol (NDC 66758-086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

5mlcarton (5mlcarton)

5mlcarton (5mlcarton)
This is information about Durezol ophthalmic emulsion with 0.05% difluprednate for ophthalmic use only. Each mL contains difluprednate, polysorbate 80, sodium chloride, edetate disodium, sodium hydroxide, water for injection. It provides usual dosage instructions, storage conditions between 15°C to 25°C, and emphasizes keeping it out of reach of children. The manufacturer is Alcon Laboratories with an expiration date of 11/2023.*
FDA Label Image

Difluprednate Structural Formula (Durezol 01)

FDA Label Image

Figure 1 Percent Of Subjects With Anterior Chamber Cells Clearing (cell Count = 0) (Durezol 02)

Figure 1 Percent Of Subjects With Anterior Chamber Cells Clearing (cell Count = 0) (Durezol 02)
This text provides information regarding the percentage of subjects with clear chamber cells on Day 8 and Day 15 of the study. It compares the results between the group receiving Durezol four times a day (n=107) and the placebo group (n=220). The data indicates a statistically significant difference on Day 15 (P<0.05).*
FDA Label Image

Figure 2 Percent Of Subjects Who Were Pain Free (Durezol 03)

Figure 2 Percent Of Subjects Who Were Pain Free (Durezol 03)
This is a statistical summary of the percentage of subjects who were pain-free on Day 3, Day 8, and Day 15 while using Durezol four times a day compared to a placebo. The study had 107 participants in the Durezol group and 220 participants in the placebo group. The results indicate a significant difference at Day 15 with a p-value less than 0.05.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.